Naming, classification, and trademark selection: Implications for market success of pharmaceutical products

Drug Information Journal

Volumn 36, Issue 4, 2002, Pages 807-824

  Gantner, Florian ^a   Schweiger, Christian ^a   Schlander, Michael ^a,b  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b University of Economics Ludwigshafer   (Germany)

Author keywords

Brand name; International Nonpropriety Name; Look alike sound alike drugs; Therapuetic class; Trademark

Indexed keywords

GENERIC DRUG;

ARTICLE; DRUG CLASSIFICATION; DRUG INDUSTRY; DRUG LABELING; DRUG MANUFACTURE; DRUG MARKETING; DRUG NOMENCLATURE; LEGAL ASPECT; MARKETING; PATENT; PRIORITY JOURNAL;

EID: 0036971376     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150203600410     Document Type: Article

References (22)

1. Center for Drug Evaluation and Research Handbook. FDA, Drug Review and Approval Times, Definitions. http://www.fda.gov/cder/reports/reviewtimes/default.htm.
2. The Use of Common Stems in the Selection of International Non-Proprietary Names (INN) for Pharmaceutical Substances. Programme on International Nonproprietary Names (INN), Division of Pharmaceutical Management & Policies; Geneva: World Health Organisation, March 1999, WHO/PHARM S/NOM 15 Rev. 37.
3. Emery P, Zeidel H, Kvien TK, Guslandi M, Naudin R, Stead H, Verburg KM, Isakson PC, Hubbard RC, Geuis GS. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet. 1999;354:2106-2111.
4. Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, Helgetveit KB, Kress B, Daniels B, Bolognese J, Krupa D, Seidenberg B, Ehrlich E. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch Int Med. 2000;160:1781-1787.
5. Bombardier C, Laine L, Reicin AD, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, Weaver A, for the VIGOR Study Group. Comparison of upper gas trointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl J Med. 2000;343:1520-1528.
6. Article 2, the European Community's First Council Directive on the Approximation of Trademark Laws 89/104/EEC, the 'Harmonisation Directive.'
7. Lane S, Phillips J. Trademark legislation and the pharmaceutical industry. London: Office of Health Economics; 1999.
8. U.S. Government Patent and Trademarks Office. http://www.uspto.gov/main/trademarks.htm.
9. Japanese Patent Office. http://www.jpo-miti.go.jp.
10. European Medicines Evaluation Agency, Committee for proprietary medicinal products. Draft guidance paper on the acceptability of tradenames for medicinal products processed through the centralised procedure. Brussels, Belgium: European Medicines Evaluation Agency. 1998; Draft, Rev.1; CPMP/328/98.
11. Caldwell JP. How to name a pharmaceutical. The Medical Post. Oct. 19, 1999;35:35.
12. Miller D. To Xanadu and back. Medical Tribune. 1999;40:12-13.
13. Starr C. When pharmaceutical names spell trouble. Pharmaceutical Topics. 2000;144:49-52.
14. Agency for Healthcare Research & Quality. Medical Errors & Patient Safety. http://www.ahrq.gov/qual/errorsix.htm.
15. U.S. Food and Drug Administration. Minimizing Product Errors. A Systematic Approach. http://www. fda.gov/oc/workshops/errorsum.htm.
16. The National Academics, Institute of Medicine Report. http://www.nas.edu/health/.
17. Institute for Safe Medication Practices. ISMP Medication Safety Alert! Newsletter, http://ismp.org/Pages/Newsletter.htm.
18. Mederrors. Educational Program: Anatomy of an Error. http://mederrors.com/search_main_set.html.
19. National Coordinating Council for Medication Error Reporting and Prevention. Council Recommendations. http://www.nccmerp.org/aboutmederrors.htm.
20. National Patient Safety Foundation. Current Research on Patient Safety in the United States. http://www.npsf.org/html/current-research.html.
21. SM 2000 Report Concepts and Cases Identifies Key Education Error Issues, http://vocuspr.vocus.com/vocuspr30/xsl/uspharm/Profile.asp.
22. Bugdahl V. Marken machen Märkte: eine Anleitung zur erfolgreichen Markenpraxis. Munich, Beck; 1998:142.